Answers are grounded in this paper and cite their sources.
PIKfyve regulates endolysosomal trafficking and late-stage autophagic processing, making it a therapeutic target in pathway-dependent tumors. This study characterized the preclinical activity, target-binding profile, pharmacokinetics, and antitumor efficacy of the 1,3,5-triazine derivative DK-AT390HCl in colorectal cancer models. DK-AT390HCl bound PIKfyve with high affinity ( K d = 5.6 nM), inhibited its kinase activity in an ADP-Glo assay (IC₅₀ = 21.5 nM) and showed favorable kinase-panel selectivity. It inhibited proliferation of murine CT26 and human SW480 and SW620 cells, with IC 50 values of 8.6–15.9 µM, while 50% growth inhibition was not reached in non-malignant colonic epithelial cells or murine fibroblasts. The compound also reduced clonogenic and CT26 spheroid growth. Treatment induced pronounced vacuolization, accumulation of MDC-positive vesicles, changes in LC3B-II, p62, and ATG5, and reduced FOXM1 abundance, consistent with altered endolysosomal and autophagy-associated processing. DK-AT390HCl achieved measurable systemic exposure. In an orthotopic CT26 model, tumor volume and tumor burden were numerically lower in all treated groups than in untreated controls, but these differences reached statistical significance only for the combination of DK-AT390HCl with 5-fluorouracil after correction for multiple comparisons. These findings identify DK-AT390HCl as a promising starting point for PIKfyve-directed colorectal cancer drug discovery, while further target validation and optimization of cellular potency, solubility, and metabolic stability remain necessary.
No takes yet. Share an insight, caveat, or question.
Kułaga et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: